Kyle J Tobler1, Gon Shoham2, Mindy S Christianson3, Yulian Zhao3, Milton Leong4, Zeev Shoham5,6. 1. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Womack Army Medical Center, Fort Bragg, NC, USA. kyle.tobler@gmail.com. 2. Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. 3. Division of Reproductive Endocrinology and Infertility, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. The Women's Clinic, Hong Kong, SAR, China. 5. Department of Obstetrics & Gynaecology, Kaplan Medical Center, Rehovot, Israel. 6. Hadassah Medical School, Jerusalem, Israel.
Abstract
PURPOSE: The aim of this study is to assess how anti-mullerian hormone (AMH) is used worldwide to test ovarian reserve and guide in vitro fertilization (IVF) cycle management. METHODS: An internet-based survey was sent electronically to registered IVF providers within the IVF-Worldwide.com network. This survey consisted of nine questions which assessed the clinics' use of AMH. The questionnaire was completed online through the IVF-Worldwide.com website, and quality assurance tools were used to verify that only one survey was completed per clinical IVF center. Results are reported as the proportion of IVF cycles represented by a particular answer choice. RESULTS: Survey responses were completed from 796 globally distributed IVF clinics, representing 593,200 IVF cycles worldwide. Sixty percent of the respondent-IVF cycles reported to use AMH as a first line test, and 54 % reported it as the best test for evaluating ovarian reserve. Eighty-nine percent reported that AMH results were extremely relevant or relevant to clinical practice. However in contrast, for predicting live birth rate, 81 % reported age as the best predictor. CONCLUSIONS: AMH is currently considered a first line test for evaluating ovarian reserve and is considered relevant to clinical practice by the majority of IVF providers.
PURPOSE: The aim of this study is to assess how anti-mullerian hormone (AMH) is used worldwide to test ovarian reserve and guide in vitro fertilization (IVF) cycle management. METHODS: An internet-based survey was sent electronically to registered IVF providers within the IVF-Worldwide.com network. This survey consisted of nine questions which assessed the clinics' use of AMH. The questionnaire was completed online through the IVF-Worldwide.com website, and quality assurance tools were used to verify that only one survey was completed per clinical IVF center. Results are reported as the proportion of IVF cycles represented by a particular answer choice. RESULTS: Survey responses were completed from 796 globally distributed IVF clinics, representing 593,200 IVF cycles worldwide. Sixty percent of the respondent-IVF cycles reported to use AMH as a first line test, and 54 % reported it as the best test for evaluating ovarian reserve. Eighty-nine percent reported that AMH results were extremely relevant or relevant to clinical practice. However in contrast, for predicting live birth rate, 81 % reported age as the best predictor. CONCLUSIONS:AMH is currently considered a first line test for evaluating ovarian reserve and is considered relevant to clinical practice by the majority of IVF providers.
Authors: Oybek Rustamov; Alexander Smith; Stephen A Roberts; Allen P Yates; Cheryl Fitzgerald; Monica Krishnan; Luciano G Nardo; Philip W Pemberton Journal: Hum Reprod Date: 2012-07-09 Impact factor: 6.918
Authors: Stamatina Iliodromiti; Thomas W Kelsey; Olivia Wu; Richard A Anderson; Scott M Nelson Journal: Hum Reprod Update Date: 2014-02-13 Impact factor: 15.610
Authors: Lisa M Pastore; Mindy S Christianson; James Stelling; William G Kearns; James H Segars Journal: J Assist Reprod Genet Date: 2017-10-02 Impact factor: 3.412